Innovation Pharmaceuticals Inc (IPIX)

[Scottwny]

Just to clarify, the 35% was the Per Protocol population which do include investigator non-compliance site. Here are the numbers I'm figuring:

ITT 200mg: 7/27 (25.9%)
PP 200mg: 7/20 (35%)
Subtract Site non-compliance: 7/16 (43.8%) - this is my assumption based on the stats. Company did not provide the actual numbers to my knowledge.

We still don't know why those 7 patients did not meet the protocol criteria, but I don't believe it has anything to do with investigator non-compliance that the company mentioned (based on stats above).